Gynecologic Cancer
At Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian Hospital, our experts at the National Cancer Institute (NCI) designated Herbert Irving Comprehensive Cancer Center (HICCC) and the Department of Obstetrics and Gynecology will combine the latest research with world-class patient care. Our faculty and researchers in the Division of Gynecologic Oncology are members of the Gynecologic Oncology Group and NRG Oncology, which brings together the best US minds in clinical research with funding from the NCI. The division participates in the nationally-recognized, interdisciplinary research, education, and patient care programs supported by the Herbert Irving Comprehensive Cancer Center (HICCC) to advance research and training to discover the best approaches for cancer prevention, diagnosis, and treatment. Our division conduct dozens of clinical trials on the latest, most promising medication treatments, targeted drugs and devices, and surgical approaches. We use the power of these discoveries made in our labs to give you personalized, comprehensive care.
Research interests in this area are focused on women with pelvic malignancies, such as cancer of the ovary, uterus, and cervix. We conduct multiple clinical trials for gynecological cancers, chemotherapy resistance, HPV and in the development of cervical dysplasia or cancer. In addition, there is ongoing clinical research focused on epidemiologic evaluation of gynecologic cancers. Specific areas of interest include ovarian, cervical, and endometrial cancer, as well as the perioperative care of women with gynecologic disease. There is also ongoing basic science research focused on the role of novel angiogenic pathways in the development and progression of gynecologic cancers.
The division has many ongoing industry-sponsored or investigator-initiated investigations, as well as a host of retrospective analysis including:
- A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FR antibody-drug conjugate) in Adult Patients with Recurrent Gynecological Cancers
- Prospective Accrual To Investigate reproductive cancers in women.
- A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 ImmunotherapyInvestigating 1L maintenance Niraparib Safety and PatIent management in REal-world ovarian cancer patients.
- Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases
- Sampling Cervical and Vaginal Biomarkers in Endometrial Neoplasms
- A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer
Faculty Active in this Area
Jason D. Wright, MD
- Sol Goldman Associate Professor of Gynecologic Oncology (in Obstetrics and Gynecology)
June Y. Hou, MD
- Associate Professor of Obstetrics & Gynecology at CUMC
Caryn M St. Clair, MD
- Assistant Professor of Obstetrics & Gynecology at CUMC
Alexandre Buckley De Meritens, MD
- Assistant Professor of OBGYN at CUMC
Tarah Pua, MD, MS
- Assistant Professor of Obstetrics and Gynecology at CUMC
Shayan Dioun, MD
- Assistant Professor of Obstetrics and Gynecology at CUMC
Thomas C Randall, MD
- Professor of Obstetrics and Gynecology at CUMC